|
1
|
Yuan XL, Lai XY, Wu YB, Yang L, Shi J, Liu
L, Zhao Y, Yu J, Huang H and Luo Y: Risk factors and prediction
model of early relapse in acute myeloid leukemia after allogeneic
hematopoietic cell transplantation. Blood. 140:12915. 2022.
View Article : Google Scholar
|
|
2
|
DiNardo CD, Erba HP, Freeman SD and Wei
AH: Acute myeloid leukaemia. Lancet. 401:2073–2086. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Toksvang LN, Lee SHR, Yang JJ and
Schmiegelow K: Maintenance therapy for acute lymphoblastic
leukemia: Basic science and clinical translations. Leukemia.
36:1749–1758. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanz MA, Fenaux P, Tallman MS, Estey EH,
Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ,
et al: Management of acute promyelocytic leukemia: Updated
recommendations from an expert panel of the European LeukemiaNet.
Blood. 133:1630–1643. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kinsella FAM, Maroto MAL, Loke J and
Craddock C: Strategies to reduce relapse risk in patients
undergoing allogeneic stem cell transplantation for acute myeloid
leukaemia. Br J Haematol. 204:2173–2183. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Molica M, Breccia M, Foa R, Jabbour E and
Kadia TM: Maintenance therapy in AML: The past, the present and the
future. Am J Hematol. 94:1254–1265. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsao T, Shi Y, Kornblau S, Lu H, Konoplev
S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, et al:
Concomitant inhibition of DNA methyltransferase and BCL-2 protein
function synergistically induce mitochondrial apoptosis in acute
myelogenous leukemia cells. Ann Hematol. 91:1861–1870. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garciaz S, Hospital MA, Alary AS, Saillard
C, Hicheri Y, Mohty B, Rey J, D'Incan E, Charbonnier A, Villetard
F, et al: Azacitidine plus venetoclax for the treatment of relapsed
and newly diagnosed acute myeloid leukemia patients. Cancers.
14:20252022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DiNardo CD, Pratz K, Pullarkat V, Jonas
BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH,
Kantarjian HM, et al: Venetoclax combined with decitabine or
azacitidine in treatment-naive, elderly patients with acute myeloid
leukemia. Blood. 133:7–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jonas BA and Pollyea DA: How we use
venetoclax with hypomethylating agents for the treatment of newly
diagnosed patients with acute myeloid leukemia. Leukemia.
33:2795–2804. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Klepin HD: Definition of unfit for
standard acute myeloid leukemia therapy. Curr Hematol Malig Rep.
11:537–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Senapati J, Kadia TM and Ravandi F:
Maintenance therapy in acute myeloid leukemia: Advances and
controversies. Haematologica. 108:2289–2304. 2023.PubMed/NCBI
|
|
13
|
Döhner H, Wei AH, Appelbaum FR, Craddock
C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian
RP, et al: Diagnosis and management of AML in adults: 2022
recommendations from an international expert panel on behalf of the
ELN. Blood. 140:1345–1377. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schuurhuis GJ, Heuser M, Freeman S, Béné
MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK,
Hourigan CS, et al: Minimal/measurable residual disease in AML: A
consensus document from the European LeukemiaNet MRD Working Party.
Blood. 131:1275–1291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
16
|
DiNardo CD, Jonas BA, Pullarkat V, Thirman
MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, et
al: Azacitidine and venetoclax in previously untreated acute
myeloid leukemia. N Engl J Med. 383:617–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wei AH, Montesinos P, Ivanov V, DiNardo
CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, et
al: Venetoclax plus LDAC for newly diagnosed AML ineligible for
intensive chemotherapy: A phase 3 randomized placebo-controlled
trial. Blood. 135:2137–2145. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pratz KW, Jonas BA, Pullarkat V, Recher C,
Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V,
Fracchiolla NS, et al: Measurable residual disease response and
prognosis in Treatment-Naïve acute myeloid leukemia with venetoclax
and azacitidine. J Clin Oncol. 40:855–865. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chua CC, Hammond D, Kent A, Tiong IS,
Konopleva MY, Pollyea DA, DiNardo CD and Wei AH: Treatment-free
remission after ceasing venetoclax-based therapy in patients with
acute myeloid leukemia. Blood Adv. 6:3879–3883. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bernardi M, Ferrara F, Carrabba MG,
Mastaglio S, Lorentino F, Vago L and Ciceri F: MRD in
Venetoclax-based treatment for AML: Does it really matter? Front
Oncol. 12:8908712022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alsouqi A, Geramita E and Im A: Treatment
of acute myeloid leukemia in older adults. Cancers (Basel).
5:54092023. View Article : Google Scholar
|
|
22
|
Xin F, Yu YH, Shen XL and Zhang GX: The
efficacy of the combination of venetoclax and hypomethylating
agents versus HAG agents in patients with acute myeloid leukemia: A
retrospective study. Hematology. 29:23503192024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rosko AE, Cordoba R, Abel G, Artz A, Loh
KP and Klepin HD: Advances in management for older adults with
hematologic malignancies. J Clin Oncol. 39:2102–2114. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patel KK, Zeidan AM, Shallis RM, Prebet T,
Podoltsev N and Huntington SF: Cost-effectiveness of azacitidine
and venetoclax in unfit patients with previously untreated acute
myeloid leukemia. Blood Adv. 5:994–1002. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Garciaz S, Dumas PY, Bertoli S, Sallman
DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C,
Laribi K, et al: Outcomes of acute myeloid leukemia patients who
responded to venetoclax and azacitidine and stopped treatment. Am J
Hematol. 99:1870–1876. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pollyea DA, DiNardo CD, Arellano ML,
Pigneux A, Fiedler W, Konopleva M, Rizzieri DA, Smith BD, Shinagawa
A, Lemoli RM, et al: Impact of venetoclax and azacitidine in
Treatment-Naïve patients with acute myeloid leukemia and IDH1/2
mutations. Clin Cancer Res. 28:2753–2761. 2022. View Article : Google Scholar : PubMed/NCBI
|
